Periodic fever syndrome

Jun 16, 2020

FDA Approves First Treatment for Adult Onset Still's Disease, a Severe and Rare Disease

Aug 07, 2019

Aevi Genomic Medicine Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody

Apr 01, 2019

Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System

Mar 28, 2019

IFM Therapeutics Announces Dosing of First Subjects in Phase 1 Healthy Volunteer Study of Lead NLRP3 Antagonist, IFM-2427

Jul 30, 2018

IFM Therapeutics Announces New Publication in Nature Reviews Drug Discovery Examining NLRP3 as a Target in Serious Inflammatory and Immune-Mediated Diseases

Jul 19, 2018

IFM Therapeutics, LLC Launches Subsidiary, IFM Tre, with $31 Million Series A Financing to Develop NLRP3 Antagonists for Inflammatory Diseases

Jan 04, 2018

ChemDiv, DZNE and Torrey Pines Investment Launch Inflammasome Discovery Program of Translational Collaboration on Neurodegeneration

Nov 16, 2017

Sobi(TM) - First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Still's Disease

May 30, 2017

Kineret® approved in Canada for the treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID)